Cite
RGFP109, a histone deacetylase inhibitor attenuates l-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: A proof-of-concept study
MLA
Sammie Damude, et al. “RGFP109, a Histone Deacetylase Inhibitor Attenuates l-DOPA-Induced Dyskinesia in the MPTP-Lesioned Marmoset: A Proof-of-Concept Study.” Parkinsonism & Related Disorders, vol. 19, Feb. 2013, pp. 260–64. EBSCOhost, https://doi.org/10.1016/j.parkreldis.2012.07.001.
APA
Sammie Damude, Steven W. Jones, James R. Rusche, Jonathan M. Brotchie, Philippe Huot, Susan H. Fox, & Tom H. Johnston. (2013). RGFP109, a histone deacetylase inhibitor attenuates l-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: A proof-of-concept study. Parkinsonism & Related Disorders, 19, 260–264. https://doi.org/10.1016/j.parkreldis.2012.07.001
Chicago
Sammie Damude, Steven W. Jones, James R. Rusche, Jonathan M. Brotchie, Philippe Huot, Susan H. Fox, and Tom H. Johnston. 2013. “RGFP109, a Histone Deacetylase Inhibitor Attenuates l-DOPA-Induced Dyskinesia in the MPTP-Lesioned Marmoset: A Proof-of-Concept Study.” Parkinsonism & Related Disorders 19 (February): 260–64. doi:10.1016/j.parkreldis.2012.07.001.